Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kala names new chair

This article was originally published in Scrip

Executive Summary

Kala Pharmaceuticals, a developer of innovative ophthalmic products based on mucus-penetrating particle (MPP) technology, has appointed Mark Iwicki executive chair and a member of its board of directors. Mr Iwicki will help guide corporate strategy and commercial preparations for Kala's lead product candidate, KPI-121, a novel nanoparticle formulation of loteprednol etabonate in development for the treatment of post-surgical ocular inflammation and pain and for dry eye and meibomian gland disease. Prior to joining Kala, Mr Iwicki was president and CEO of Civitas Therapeutics, a company acquired by Acorda Therapeutics in 2014.

You may also be interested in...



In Vivo's Top M&A Of 2019: Cast Your Vote!

It is time for In Vivo's 12th annual Deals of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.

In Vivo's Top Alliance Of 2019: Cast Your Vote!

It is time for In Vivo's 12th annual Deals of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.

In Vivo's Top Financing Of 2019: Cast Your Vote!

It is time for In Vivo's 12th annual Deals of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.

Topics

Related Companies

UsernamePublicRestriction

Register

SC028794

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel